https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/biofil-chemicals-pharmaceuticals-ltd.png Logo

Biofil Chemicals Pharmaceuticals Ltd Financial Statement

Biofil Chemicals Pharmaceuticals Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Mar 2024Dec 2023Sep 2023
Revenue15.615.0617.4
Operating Expense15.244.8417.13
Net Profit0.250.090.12
Net Profit Margin1.61.780.69
Earning Per Share0.150.060.08
EBIDTA0.460.220.27
Effective Tax Rate29.739.0911.11

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Biofil Chemicals Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual30.0422.3835.75
Operating Expenses Annual28.8721.0534.15
Operating Profit Annual1.261.482.4
Interest Annual0.040.040.07
Depreciation0.430.430.41
Net Profit Annual0.560.71.24
Tax Annual0.230.320.68

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Biofil Chemicals Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning0.140.440.26
Cash Flow from Operations-0.11-0.221.11
Cash Flow from Investing-0.01-0.07-0.1
Cash Flow from Financing0.02-0.01-0.83
Cash Flow at the End0.040.140.44

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Biofil Chemicals Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)4.196.616.71
PBIT Margin (%)2.764.695.57
PBT Margin (%)-66.31-113.72-73.95
Net PROFIT Margin (%)1.863.133.47
Return On Networth / Equity (%)1.121.42.49
Return On Networth /Employed(%)1.652.113.92
Return On Assets (%)3.194.137.6
Total Debt / Equity(X)0.030.030.05
Asset Turnover Ratio (%)1.711.322.19

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Biofil Chemicals Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual99.429.78
Total Current Assets Annual22.419.3123.46
Non Current Assets Annual99.429.78
Total Shareholders Funds Annual17.316.8416.13
Total Assets Annual31.4118.7333.24

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of June 22, 2024, Biofil Chemicals Pharmaceuticals Ltd has a market capitalization of 98.21 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Biofil Chemicals Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.02.

In FY 2023, Biofil Chemicals Pharmaceuticals Ltd recorded a total revenue of approximately 40.04 Cr marking a significant milestone in the company's financial performance.

Biofil Chemicals Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.0% and 0.3% annually, respectively..

Biofil Chemicals Pharmaceuticals Ltd's current PE ratio is 138.32.

Biofil Chemicals Pharmaceuticals Ltd's ROCE averaged 5.2% from the FY ending March 2022 to 2024, with a median of 4.9%. It peaked at 6.1% in March 2022, reflecting strong capital efficiency over the period..

Biofil Chemicals Pharmaceuticals Ltd's latest EBIT is Rs. 0.91 Cr, surpassing the average EBIT of Rs. 0.93 Cr over the 5 years..